These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 38399961)

  • 1. SARS-CoV-2 Specific Nanobodies Neutralize Different Variants of Concern and Reduce Virus Load in the Brain of h-ACE2 Transgenic Mice.
    Pavan MF; Bok M; Betanzos San Juan R; Malito JP; Marcoppido GA; Franco DR; Militelo DA; Schammas JM; Bari SE; Stone W; López K; Porier DL; Muller JA; Auguste AJ; Yuan L; Wigdorovitz A; Parreño VG; Ibañez LI
    Viruses; 2024 Jan; 16(2):. PubMed ID: 38399961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanobodies against SARS-CoV-2 reduced virus load in the brain of challenged mice and neutralized Wuhan, Delta and Omicron Variants.
    Pavan MF; Bok M; Juan RBS; Malito JP; Marcoppido GA; Franco DR; Militello DA; Schammas JM; Bari S; ; Stone WB; López K; Porier DL; Muller J; Auguste AJ; Yuan L; Wigdorovitz A; Parreño V; Ibañez LI
    bioRxiv; 2023 Mar; ():. PubMed ID: 36993215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanobodies with cross-neutralizing activity provide prominent therapeutic efficacy in mild and severe COVID-19 rodent models.
    Han Q; Wang S; Wang Z; Zhang C; Wang X; Feng N; Wang T; Zhao Y; Chi H; Yan F; Xia X
    Virol Sin; 2023 Oct; 38(5):787-800. PubMed ID: 37423308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration.
    Wu X; Cheng L; Fu M; Huang B; Zhu L; Xu S; Shi H; Zhang D; Yuan H; Nawaz W; Yang P; Hu Q; Liu Y; Wu Z
    Cell Rep; 2021 Oct; 37(3):109869. PubMed ID: 34644535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than Omicron.
    Casasnovas JM; Margolles Y; Noriega MA; Guzmán M; Arranz R; Melero R; Casanova M; Corbera JA; Jiménez-de-Oya N; Gastaminza P; Garaigorta U; Saiz JC; Martín-Acebes MÁ; Fernández LÁ
    Front Immunol; 2022; 13():863831. PubMed ID: 35547740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biparatopic nanobodies protect mice from lethal challenge with SARS-CoV-2 variants of concern.
    Wagner TR; Schnepf D; Beer J; Ruetalo N; Klingel K; Kaiser PD; Junker D; Sauter M; Traenkle B; Frecot DI; Becker M; Schneiderhan-Marra N; Ohnemus A; Schwemmle M; Schindler M; Rothbauer U
    EMBO Rep; 2022 Feb; 23(2):e53865. PubMed ID: 34927793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational design of novel nanobodies targeting the receptor binding domain of variants of concern of SARS-CoV-2.
    Longsompurana P; Rungrotmongkol T; Plongthongkum N; Wangkanont K; Wolschann P; Poo-Arporn RP
    PLoS One; 2023; 18(10):e0293263. PubMed ID: 37874836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice.
    Cai JP; Luo C; Wang K; Cao H; Chen LL; Zhang X; Han Y; Yin F; Zhang AJ; Chu H; Yuan S; Kok KH; To KK; Chen H; Chen Z; Jin DY; Yuen KY; Chan JF
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses.
    Li M; Ren Y; Aw ZQ; Chen B; Yang Z; Lei Y; Cheng L; Liang Q; Hong J; Yang Y; Chen J; Wong YH; Wei J; Shan S; Zhang S; Ge J; Wang R; Dong JZ; Chen Y; Shi X; Zhang Q; Zhang Z; Chu JJH; Wang X; Zhang L
    Nat Commun; 2022 Dec; 13(1):7957. PubMed ID: 36575191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.
    Yang J; Zhang Z; Yang F; Zhang H; Wu H; Zhu F; Xue W
    Chem Biol Drug Des; 2021 Jul; 98(1):1-18. PubMed ID: 33894099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization.
    Kim Y; Gaudreault NN; Meekins DA; Perera KD; Bold D; Trujillo JD; Morozov I; McDowell CD; Chang KO; Richt JA
    Microbiol Spectr; 2022 Jun; 10(3):e0178921. PubMed ID: 35638818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern
    Chiem K; Morales Vasquez D; Silvas JA; Park JG; Piepenbrink MS; Sourimant J; Lin MJ; Greninger AL; Plemper RK; Torrelles JB; Walter MR; de la Torre JC; Kobie JK; Ye C; Martinez-Sobrido L
    J Virol; 2021 Oct; 95(22):e0112621. PubMed ID: 34495697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice.
    Lee KS; Rader NA; Miller-Stump OA; Cooper M; Wong TY; Shahrier Amin M; Barbier M; Bevere JR; Ernst RK; Heath Damron F
    Vaccine; 2023 Jul; 41(34):5003-5017. PubMed ID: 37407405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants.
    Xu J; Xu K; Jung S; Conte A; Lieberman J; Muecksch F; Lorenzi JCC; Park S; Schmidt F; Wang Z; Huang Y; Luo Y; Nair MS; Wang P; Schulz JE; Tessarollo L; Bylund T; Chuang GY; Olia AS; Stephens T; Teng IT; Tsybovsky Y; Zhou T; Munster V; Ho DD; Hatziioannou T; Bieniasz PD; Nussenzweig MC; Kwong PD; Casellas R
    Nature; 2021 Jul; 595(7866):278-282. PubMed ID: 34098567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deconstructing SARS-CoV-2 neutralization: A modular molecular framework for computational design and comparison of antibodies and nanobodies targeting the spike RBD.
    Tragni V; Mercurio I; Paoletti DP; Onofrio A; Laera L; Cafferati Beltrame L; Sgobba MN; Guerra L; Volpicella M; De Grassi A; Elia G; Pierri CL
    J Med Virol; 2023 Jun; 95(6):e28875. PubMed ID: 37338047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
    Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron.
    Ma H; Zhang X; Zheng P; Dube PH; Zeng W; Chen S; Cheng Q; Yang Y; Wu Y; Zhou J; Hu X; Xiang Y; Zhang H; Chiu S; Jin T
    Cell Res; 2022 Sep; 32(9):831-842. PubMed ID: 35906408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity.
    Chen WH; Hajduczki A; Martinez EJ; Bai H; Matz H; Hill TM; Lewitus E; Chang WC; Dawit L; Peterson CE; Rees PA; Ajayi AB; Golub ES; Swafford I; Dussupt V; David S; Mayer SV; Soman S; Kuklis C; Corbitt C; King J; Choe M; Sankhala RS; Thomas PV; Zemil M; Wieczorek L; Hart T; Duso D; Kummer L; Yan L; Sterling SL; Laing ED; Broder CC; Williams JK; Davidson E; Doranz BJ; Krebs SJ; Polonis VR; Paquin-Proulx D; Rolland M; Reiley WW; Gromowski GD; Modjarrad K; Dooley H; Joyce MG
    Nat Commun; 2023 Feb; 14(1):580. PubMed ID: 36737435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.